Resource Logo
AIDS Weekly Plus

Investigators at Johns Hopkins University Bloomberg School of Public Health Report Findings in HAART




 



2013 APR 15 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Researchers detail new data in HAART. According to news reporting originating in Baltimore, Maryland, by NewsRx journalists, research stated, "To explore immunologic risk factors for death within 90 days of highly active antiretroviral therapy (HAART) initiation, CD4(+) and CD8(+) T cell subsets were measured by flow cytometry and characterized by logistic regression in 149 Zambian children between 9 months and 10 years of age enrolled in a prospective, observational study of the impact of HAART on measles immunity. Of 21 children who died during follow-up, 17 (81%) had known dates of death and 16 (76%) died within 90 days of initiating HAART."

The news reporters obtained a quote from the research from the Johns Hopkins University Bloomberg School of Public Health, "Young age and low weight-for-age z-scores were associated with increased risks of mortality within 90 days of starting HAART, whereas CD4(+) T cell percentage was not associated with mortality. After adjusting for these factors, each 10% increase in CD8(+) effector T cells increased the odds of overall mortality [OR = 1.43 (95% CI: 1.08, 1.90)] and was marginally associated with early mortality [OR = 1.29 (95% CI: 0.97, 1.72)]. Conversely, each 10% increase in CD4+ central memory T cells decreased the odds of overall [OR = 0.06 (95% CI: 0.01, 0.59)] and early mortality [OR = 0.09 (95% CI: 0.01, 0.97)]. Logistic regression prediction models demonstrated areas under the receiver-operator characteristic curves of >= 85% for early and overall mortality, with bootstrapped sensitivities of 82-85% upon validation, supporting the predictive accuracy of the models."

According to the news reporters, the research concluded: "CD4(+) and CD8(+) T cell subsets may be more accurate predictors of early mortality than CD4(+) T cell percentages and could be used to identify children who would benefit from more frequent clinical monitoring after initiating HAART."

For more information on this research see: Immunologic Risk Factors for Early Mortality After Starting Antiretroviral Therapy in HIV-Infected Zambian Children. Aids Research and Human Retroviruses, 2013;29(3):479-487. Aids Research and Human Retroviruses can be contacted at: Mary Ann Liebert Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Aids Research and Human Retroviruses - www.liebertpub.com/overview/aids-research-and-human-retroviruses/2/)

Our news correspondents report that additional information may be obtained by contacting K. Rainwater-Lovett, Johns Hopkins Bloomberg Sch Public Hlth, W Harry Feinstone Dept. of Mol Microbiol & Immunol, Baltimore, MD 21205, United States (see also HAART).

Keywords for this news article include: Drugs, HAART, Maryland, HIV/AIDS, Baltimore, Pediatrics, RNA Viruses, Retroviridae, United States, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, Clinical Trial Research, North and Central America, Viral Sexually Transmitted Diseases, Highly Active Antiretroviral Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC



 


Copyright © 2013 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in April 15, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.